<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0005">
 <label>Table 1</label>
 <caption>
  <p>Potential COVID-19 therapeutics currently under clinical investigation.</p>
 </caption>
 <alt-text id="al0010">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Therapeutic</th>
    <th>Mechanism</th>
    <th>Initial usage</th>
    <th>Cardiac implementation</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="4">Inhibition of the viral cell entry and virus spreading</td>
   </tr>
   <tr>
    <td>Camostat mesylate</td>
    <td>
     <list list-type="simple" id="l0005">
      <list-item id="li0005">
       <label>1.</label>
       <p id="p0005">Inhibitor of serine proteases, especially transmembrane protease serine subtype 2 (TMPRSS2),</p>
      </list-item>
      <list-item id="li0010">
       <label>2.</label>
       <p id="p0010">Protease important for SARS-CoV2 S-protein cleavage for viral membrane fusion.</p>
      </list-item>
     </list>
    </td>
    <td>Therapeutic against pancreatitis
     <break/>Inhibition of pancreatic fibrosis
    </td>
    <td>
     <list list-type="simple" id="l0010">
      <list-item id="li0015">
       <label>•</label>
       <p id="p0015">Additional function: Inhibition of monocyte activation and reduced TNFα-production,</p>
      </list-item>
      <list-item id="li0020">
       <label>•</label>
       <p id="p0020">Reduction of detrimental proinflammatory mechanisms in the heart.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Antiproteases (anti-plasmin)</td>
    <td>
     <list list-type="simple" id="l0015">
      <list-item id="li0025">
       <label>1.</label>
       <p id="p0025">Inhibition of endogenous proteases responsible for SARS-CoV2 S-protein cleavage into S1- and S2-subunit (TMPRSS2, Cathepsin B/L, 
        <bold>plasmin</bold>)
       </p>
      </list-item>
      <list-item id="li0030">
       <label>2.</label>
       <p id="p0030">Increased plasmin during SARS-CoV2 leads to increased fibrin degradation products (FDPs), hyperfibrinolysis and reduced platelet conc.</p>
      </list-item>
     </list>
    </td>
    <td/>
    <td>
     <list list-type="simple" id="l0020">
      <list-item id="li0035">
       <label>•</label>
       <p id="p0035">Disturbed blood coagulation may lead to hemophilia or thrombosis,</p>
      </list-item>
      <list-item id="li0040">
       <label>•</label>
       <p id="p0040">anti-proteases directed against plasmin could reverse those effects</p>
      </list-item>
      <list-item id="li0045">
       <label>•</label>
       <p id="p0045">Plasmin additionally induces hypertension by activation of Na
        <sup>+</sup>-retention
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Chloroquine phosphate
     <break/>Hydroxychloroquine
    </td>
    <td>
     <list list-type="simple" id="l0025">
      <list-item id="li0050">
       <label>1.</label>
       <p id="p0050">Interference with the pH-dependent endosome-mediated entry of SARS-CoV2 by increasing the pH of acidic vesicles</p>
      </list-item>
      <list-item id="li0055">
       <label>2.</label>
       <p id="p0055">Interference of the sialic acid biosynthesis pathway via inhibition of quinone reductase 2, which leads to a disturbed glycosylation of viral entry receptor ACE-2</p>
      </list-item>
      <list-item id="li0060">
       <label>3.</label>
       <p id="p0060">Interference with post-translational modification of viral proteins (proteases)</p>
      </list-item>
      <list-item id="li0065">
       <label>4.</label>
       <p id="p0065">Inhibition of IFNα- and IL-6 expression (anti-inflammatory effect)</p>
      </list-item>
     </list>
    </td>
    <td>Therapeutic against malaria
     <break/>
     <break/>Hydroxychloroquine: therapeutic against rheumatoid arthritis
    </td>
    <td>
     <list list-type="simple" id="l0030">
      <list-item id="li0070">
       <label>•</label>
       <p id="p0070">Treatment with chloroquine/hydroxychloroquine leads to a drug-induced QT-interval prolongation.</p>
      </list-item>
      <list-item id="li0075">
       <label>•</label>
       <p id="p0075">Consequence: torsades de pointes (TdP) tachycardia and increased risk of arrhythmic</p>
      </list-item>
      <list-item id="li0080">
       <label>•</label>
       <p id="p0080">high-risk especially when combined with azithromycin treatment (s. below)</p>
      </list-item>
      <list-item id="li0085">
       <label>•</label>
       <p id="p0085">thorough QT-monitoring necessary</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Umifenovir (Arbidol)</td>
    <td>
     <list list-type="simple" id="l0035">
      <list-item id="li0090">
       <label>1.</label>
       <p id="p0090">Membrane fusion inhibitor by interaction with hemagglutinin of influenza A</p>
      </list-item>
      <list-item id="li0095">
       <label>2.</label>
       <p id="p0095">Exact mechanism for treatment of SARS-CoV2 not elucidated</p>
      </list-item>
     </list>
    </td>
    <td>Therapeutic against influenza A</td>
    <td>
     <list list-type="simple" id="l0040">
      <list-item id="li0100">
       <label>•</label>
       <p id="p0100">protection against other viral infections with heart tropism like Coxsackie virus B5</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Soluble human recombinant ACE2 (hrACE2)</td>
    <td>Neutralization of SARS-CoV2 via competitive binding of hrACE2, decelerated virus entry and spread</td>
    <td/>
    <td>
     <list list-type="simple" id="l0045">
      <list-item id="li0105">
       <label>•</label>
       <p id="p0105">SARS-CoV2 infection and resulting ACE2-downregulation = increased AngII conc. and thereby hypertension and vasoconstriction</p>
      </list-item>
      <list-item id="li0110">
       <label>•</label>
       <p id="p0110">Soluble hrACE2 rescues ACE2 function in lung and heart</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td colspan="4">  </td>
   </tr>
   <tr>
    <td colspan="4">Inhibition of the viral RNA-synthesis</td>
   </tr>
   <tr>
    <td>Remdesivir</td>
    <td>Nucleosid-analogue for the selective inhibition of the viral RdRp</td>
    <td>Therapeutic against Ebola virus</td>
    <td>
     <list list-type="simple" id="l0050">
      <list-item id="li0115">
       <label>•</label>
       <p id="p0115">Increases lung function and decreases viral load</p>
      </list-item>
      <list-item id="li0120">
       <label>•</label>
       <p id="p0120">Recent studies only show moderate improvement in severe case patients (larger cohorts necessary to evaluate effectivity)</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Lopinavir/Ritonavir</td>
    <td>Protease-inhibitor: Most likely inhibits viral 3-chemotrypsine-like protease</td>
    <td>HIV-protease inhibitor</td>
    <td>
     <list list-type="simple" id="l0055">
      <list-item id="li0125">
       <label>•</label>
       <p id="p0125">Effectivity against SARS-CoV2 questionable</p>
      </list-item>
      <list-item id="li0130">
       <label>•</label>
       <p id="p0130">Side effects: hypertriglyceridemia, hypercholesterinemia, hypertension</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Ribavirin</td>
    <td>Nucleosid-analogue for the inhibition of the viral RdRp</td>
    <td>Therapeutic against hepatitis C, etc.</td>
    <td>
     <list list-type="simple" id="l0060">
      <list-item id="li0135">
       <label>•</label>
       <p id="p0135">Effectivity against SARS-CoV2 questionable</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Favipiravir</td>
    <td>Nucleosid-analogue for the selective inhibition of the viral RdRp</td>
    <td>Therapeutic against influenza and ebola virus</td>
    <td>
     <list list-type="simple" id="l0065">
      <list-item id="li0140">
       <label>•</label>
       <p id="p0140">Decreased fever duration</p>
      </list-item>
      <list-item id="li0145">
       <label>•</label>
       <p id="p0145">Increased clearance of viral particles</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td colspan="4">  </td>
   </tr>
   <tr>
    <td colspan="4">Immunotherapeutic, Immunosuppressive</td>
   </tr>
   <tr>
    <td>Interferons [IFN-α]</td>
    <td>Induction of the expression of antiviral genes and the antiviral immune response</td>
    <td/>
    <td>
     <list list-type="simple" id="l0070">
      <list-item id="li0150">
       <label>•</label>
       <p id="p0150">Inflammation</p>
      </list-item>
      <list-item id="li0155">
       <label>•</label>
       <p id="p0155">No benefit in mortality during clinical studies</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Anakinra</td>
    <td>Immunosuppression by inhibition of IL-1-R</td>
    <td>Attenuation of cytokine storm in CAR-T cell therapy</td>
    <td>
     <list list-type="simple" id="l0075">
      <list-item id="li0160">
       <label>•</label>
       <p id="p0160">Anti-inflammatory effect in the heart</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Toclizumab/Siltuximab</td>
    <td>Immunosuppression by inhibition of IL-6-R (Toclizumab) and IL-6 (Siltuximab)</td>
    <td>Attenuation of cytokine storm in CAR-T cell therapy</td>
    <td>
     <list list-type="simple" id="l0080">
      <list-item id="li0165">
       <label>•</label>
       <p id="p0165">Anti-inflammatory effect in the heart</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>other immunothe rapeutics: Azithromycin</td>
    <td>Stimulation of host antiviral response through the induction of interferons and IFN-stimulated genes (ISGs)</td>
    <td>Macrolide antibiotic against bacterial infections (e.g. 
     <italic>P. aeruginosa</italic>)
    </td>
    <td>
     <list list-type="simple" id="l0085">
      <list-item id="li0170">
       <label>•</label>
       <p id="p0170">Azithromycin leads to a drug-induced QT-interval prolongation via inhibition of iKr</p>
      </list-item>
      <list-item id="li0175">
       <label>•</label>
       <p id="p0175">Consequence: torsades de pointes (TdP) tachycardia</p>
      </list-item>
      <list-item id="li0180">
       <label>•</label>
       <p id="p0180">Increased risk of arrhythmic death</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td colspan="4">Anti-hypertension therapeutics and potential SARS-CoV2 vaccines</td>
   </tr>
   <tr>
    <td colspan="4">  </td>
   </tr>
   <tr>
    <td>ACE-inhibitors
     <break/>AT
     <sub>1</sub>-antagonists (Losartan)
    </td>
    <td>Inhibition of ACE-1 leads to:
     <break/>
     <list list-type="simple" id="l0090">
      <list-item id="li0185">
       <label>1.</label>
       <p id="p0185">less angiotensin II</p>
      </list-item>
      <list-item id="li0190">
       <label>2.</label>
       <p id="p0190">increased levels of ACE-2 (controversial).</p>
      </list-item>
      <list-item id="li0195">
       <label>3.</label>
       <p id="p0195">ACE-2 product angiotensin 1–7 has a vasodilatory effect</p>
      </list-item>
     </list>
    </td>
    <td/>
    <td>
     <list list-type="simple" id="l0095">
      <list-item id="li0200">
       <label>•</label>
       <p id="p0200">Increased ACE-2 level initially might result in a higher viral uptake</p>
      </list-item>
      <list-item id="li0205">
       <label>•</label>
       <p id="p0205">Withdrawal of ACE-inhibitors might be detrimental, since Ang II might be responsible for acute lung injury</p>
      </list-item>
      <list-item id="li0210">
       <label>•</label>
       <p id="p0210">ACEII possesses cardioprotective effect</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>monoclonal neutralizing AB</td>
    <td>
     <list list-type="simple" id="l0100">
      <list-item id="li0215">
       <label>1.</label>
       <p id="p0215">SARS-CoV2 specific Abs isolated from convalescent patients</p>
      </list-item>
      <list-item id="li0220">
       <label>2.</label>
       <p id="p0220">Cross-reactivity of mABs from SARS and MERS</p>
      </list-item>
     </list>
    </td>
    <td/>
    <td>
     <list list-type="simple" id="l0105">
      <list-item id="li0225">
       <label>•</label>
       <p id="p0225">Risk of immunopathogenic liver reaction by antibody-dependent enhancement of the disease</p>
      </list-item>
     </list>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
